Combining Breast, Lung Cancer Therapies Could Overcome Treatment Resistance

Combining Breast, Lung Cancer Therapies Could Overcome Treatment Resistance
Combining Ibrance (palbociclib), a treatment for advanced breast cancer, with the lung cancer medicine crizotinib is more effective against human cancer cells in the laboratory than either drug alone, scientists have found. The researchers say the findings suggest the combination could be used to overcome treatment resistance in some breast cancers, as well as broaden the clinical use of Ibrance as a promising treatment for many other tumor types, including lung cancer. Their study, "Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases," was published in the journal Oncogene. “Cancer’s ability to adapt, evolve, and become drug resistant is the biggest challenge we face in creating more effective treatments for the disease. In this study, we sought to understand exactly how resistance occurs to an important family of breast cancer drugs, so that we can stay one step ahead of the cancer," study co-leader Paul Workman, chief executive of The Institute of Cancer Research, London, said in a press release. According to scientists, Ibrance (by Pfizer) h
Subscribe or to access all post and page content.